|
|
Reglan (Metoclopramide HCI)
|
 |
Gastrointestinal agent
|
 |
GI stimulant
|
 |
Prevention or reduction of nausea and vomiting induced by highly emetogenic chemotherapy, facilitation of small-bowel intubation and to aid in radiologic examinations, delayed gastric emptying secondary to diabetic gastroparesis, postoperative nausea and vomiting, lactation improvement, gastroesphageal Reflux, nausea and vomiting associated with cancer chemotherapy and postoperative recovery.
|
 |
10-15 mg 4 times daily before meals and bedtime.
|
 |
Category B
|
 |
Restlessness, drowsiness, fatigue, dizziness, Anxiety, Insomnia, headache, nausea, Diarrhea, akathsia, suicidal ideation, Seizures, Bradycardia, bowel disturbances, incontinence, agranulcoytosis, bronchospasm, Urticaria, prolactic secretion.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
